07Dec

FIRST IVDR CERTIFICATE ISSUED BY TÜV SÜD

The new In Vitro Diagnostic Medical Device Regulation (IVDR, EU 2017/746) of the European Union replaces Directive 98/79/EC on In Vitro Medical Devices (IVDD). It represents a significant regulation change which imposes stricter demands on medical device manufacturers and Notified Bodies. To date, 4 of the 11 Notified Bodies which have applied for designation under IVDR have received designation and are published on the NANDO webpage.

TÜV SÜD is pleased to announce that it has issued the first IVDR certificate, a certificate for a Class B device.

“Since receiving designation and notification, TÜV SÜD has been working hard on reorganising and preparing resources to provide services under the new legislative framework. We have continued to clarify open questions and implement newly published information about the IVDR into our processes. The release of our first IVDR certificate is a significant milestone. The challenge now lies in balancing our existing IVDD projects with the strong demand for IVDR services in this transition period”, says Dr Andreas Stange, Vice President / Medical & Health Services at TÜV SÜD.

"Our issue of the first IVDR certificate in such a short time after receiving our designation as a Notified Body, demonstrates our commitment under this new status to support effective implementation of the IVDR and a smooth transition from the old directive to the new regulation. It is critical that a continued supply of safe and effective medical devices is available for patients and healthcare professionals”, adds Dr Royth von Hahn, Senior Vice President / Global Head of Medical & Health Services at TÜV SÜD.
 

TÜV SÜD'S INTERNATIONAL EXPERTISE

TÜV SÜD is one of the world's leading Notified Bodies providing conformity assessment services related to medical devices. Its 900-plus medical device professionals can be found at more than 30 locations throughout the world. Manufacturers benefit from both TÜV SÜD's technical expertise and its extensive international accreditations and recognitions, including NRTL, INMETRO and the Medical Device Single Audit Program (MDSAP). These benefits considerably reduce the efforts involved in accessing international markets and time to market.

Further information about the EU In Vitro Diagnostic Medical Device Regulation, the key changes it involves and TÜV SÜD's services in this context can be found at https://www.tuvsud.com/ivdr.

Related

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC

New molecular assay enables rapid antibiotic resistance result to support use of cost effective and ...

Read More >

Member Press Release - Life Science Group receives ISO 13485 accreditation

Life Science Group receives ISO 13485 accreditation. Life Science Group (LSG), one of the UK...

Read More >

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch ...

Read More >

North East Innovation Lab supports Newcastle University study into new Covid-19 test

The North East Innovation Lab has played a key role in a successful study to develop a new biosensor...

Read More >

MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated I...

Read More >

OGT continues move into molecular diagnostics markets with MDSAP certification

Certification of new Cambridge facility smooths path to future IVD approvals

Read More >